Clinical & Translational Oncology

SCIE

國際簡稱：CLIN TRANSL ONCOL 參考譯名：臨床和轉(zhuǎn)化腫瘤學(xué)

主要研究方向：腫瘤學(xué)-醫(yī)學(xué) 非預(yù)警期刊審稿周期：約2.2月

《臨床和轉(zhuǎn)化腫瘤學(xué)》(Clinical & Translational Oncology)是一本由Springer International Publishing出版的以腫瘤學(xué)-醫(yī)學(xué)為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。

3區(qū) 中科院分區(qū)
Q2 JCR分區(qū)
287 年發(fā)文量
2.8 IF影響因子
未開放 是否OA
42 H-index
2000 創(chuàng)刊年份
Monthly 出版周期
English 出版語言

Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.

[ 查看全部 ]

投稿咨詢加急咨詢

Clinical & Translational Oncology期刊信息

ISSN：1699-048X
出版語言：English
是否OA：未開放
E-ISSN：1699-3055
出版地區(qū)：SPAIN
是否預(yù)警：否
出版商：Springer International Publishing
出版周期：Monthly
創(chuàng)刊時間：2000
開源占比：0.1792
Gold OA文章占比：21.58%
OA被引用占比：0.2184...
出版國人文章占比：0.25
出版撤稿占比：0
研究類文章占比：75.61%

Clinical & Translational Oncology CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

6.2

0.837

0.79

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q2	121 / 404	70%
大類：Medicine 小類：Cancer Research	Q2	101 / 230	56%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標(biāo)。當(dāng)年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Clinical & Translational Oncology中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

Clinical & Translational Oncology JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q2	157 / 322	51.4%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q3	177 / 322	45.19%

Clinical & Translational Oncology歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

Clinical & Translational Oncology中國學(xué)者發(fā)文選摘

1、Tumor mutational burden and efficacy of chemotherapy in lung cancer
Author: Song, Juan; Yan, Yu; Chen, Cuicui; Li, Jiamin; Ding, Ning; Xu, Nuo; Bao, Hairong; Zhang, Xin; Hong, Qunying; Zhou, Jian; Shao, Yang W.; Song, Yuanlin; Tong, Lin; Hu, Jie

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 173-184. DOI: 10.1007/s12094-022-02924-6
2、The correlations between psychological distress, cognitive impairment and quality of life in patients with brain metastases after whole-brain radiotherapy
Author: Yao, Senbang; Zuo, He; Li, Wen; Cai, Yinlian; Zhang, Qianqian; Pang, Lulian; Jing, Yanyan; Yin, Xiangxiang; Cheng, Huaidong

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 207-217. DOI: 10.1007/s12094-022-02927-3
3、A research review of experimental animal models with myelodysplastic syndrome
Author: Chen, Gen-Wang; Chen, Mei-Na; Liu, Lei; Zheng, Yu-Yu; Wang, Jin-Peng; Gong, Si-Si; Huang, Rong-Fu; Fan, Chun-Mei; Chen, Yue-Zu

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 105-113. DOI: 10.1007/s12094-022-02931-7
4、The pleiotropic mode and molecular mechanism of macrophages in promoting tumor progression and metastasis
Author: Zhang, Xingxing; Bai, Wenxiu; Hu, Lisha; Ha, Hualan; Du, Yuelin; Xiong, Wei; Wang, Hongbo; Shang, Panfeng

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 91-104. DOI: 10.1007/s12094-022-02932-6
5、Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy
Author: Chen, Dujuan; Qin, Hongyue; Deng, Guangchuan; Wang, Qi; Wang, Haiyong; Liu, Xijun

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 226-235. DOI: 10.1007/s12094-022-02936-2
6、DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer
Author: Li, Yuan; Liao, Leen; Kong, Lingheng; Jiang, Wu; Tang, Jinghua; Han, Kai; Hou, Zhenlin; Zhang, Chenzhi; Zhou, Chi; Zhang, Linjie; Sui, Qiaoqi; Xiao, Binyi; Mei, Weijian; Xu, Yanbo; Yu, Jiehai; Hong, Zhigang; Pan, Zhizhong; Ding, Peirong

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 218-225. DOI: 10.1007/s12094-022-02930-8
7、The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease
Author: Lu, Juan; Zhu, Danhua; Zhang, Xiaoqian; Wang, Jie; Cao, Hongcui; Li, Lanjuan

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 137-150. DOI: 10.1007/s12094-022-02943-3
8、Targeted delivery of nuclear targeting probe for bladder cancer using cyclic pentapeptide c(RGDfK) and acridine orange
Author: Qin, Jiaxin; Liang, Qing; Wang, Guangyue; Hao, Lin; Liu, Xing; Wang, Xinlei; Hu, Zhengxiang; Fang, Gaochuan; Xue, Liang; Zhao, Yan; Li, Rui; Lv, Qian; Wen, Jiling; Yang, Guosheng; Han, Conghui; Shi, Zhenduo

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 2, pp. 375-383. DOI: 10.1007/s12094-022-02938-0